Loading...
Market
Which age group will primarily receive Moderna's mRNA-1083 vaccine by end of 2025?
4
Resolution / Starting Odds
50 and older • 33%
30-49 • 33%
Under 30 • 33%
Vaccination statistics, healthcare reports
Story
Moderna's mRNA-1083 Combo COVID-19 and Flu Vaccine Shows Strong Phase 3 Results
Jun 10, 2024, 01:10 PM
Moderna announced that its investigational combination vaccine, mRNA-1083, which targets both COVID-19 and seasonal influenza, has shown positive results in a Phase 3 late-stage trial. The vaccine generated a stronger immune response in adults aged 50 and over compared to separate shots for each virus. The combination vaccine was found to be more effective than existing standalone vaccines, including Moderna's own Spikevax. The success of the trial brings Moderna closer to potentially filing for regulatory approval, with market availability anticipated as early as fall 2025. Moderna CEO Stephane Bancel highlighted the convenience and potential benefits of combination vaccines, especially in the context of labor shortages in healthcare.
View original story
Similar markets
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Over 60% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Under $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Recommendation against vaccines for under 50s • 25%
No change in current recommendation • 25%
Stronger endorsement of vaccines for under 50s • 25%
Recommendation under review • 25%